ArticleAmerican journal of cancer research2022
Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer.
Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- ITGB2 related to immune cell infiltration as a potential therapeutic target of inflammatory bowel disease using bioinformatics and functional research.Journal of cellular and molecular medicine · 2024Article
- Article
- Identification of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in alimentary tract malignancies.BMC bioinformatics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis is a novel type of cell death that may play a vital role in preventing various types of cancer. Studies examining cuproptosis are limited, and the cuproptosis-related lncRNAs (long non-Coding ribonucleic acids) involved in the regulation of colon cancer remain unclear. This study aimed to identify the prognostic signature of cupronosis-related lncRNAs and explore their potential molecular functions in colon cancer. Data on the clinical correlation were obtained from The Cancer Genome Atlas (TCGA) database. The differentially expressed cuproptosis-related long non-coding ribonucleic acids (lncRNAs) were analyzed using the "limma" package. Then, the prognostic cuproptosis-related lncRNA signature (CupRLSig) was identified through univariate Cox and co-expression analyses, and a prognostic model was constructed based on CupRLSig using the least absolute shrinkage selection operator (LASSO) algorithm and Cox regression analysis. The Kaplan-Meier survival curve and receiver operating characteristic (ROC) curve were used for evaluating the model's capacity for prognosis prediction. In addition, the immune landscape, and drug sensitivity of CupRLSig were analyzed. Finally, the functions of AL512306.3 and ZEB1-AS1 were verified through in vitro experiments. The high- or low-risk groups were classified according to the risk score. The signature-based risk score showed a stronger ability to predict patient's survival compared with the traditional clinicopathological features. In addition, immune responses, such as inflammation-promoting response and T-cell co-inhibition, were significantly different between the two groups. Moreover, chemotherapy drugs or inhibitors, such as axitinib, cisplatin, doxorubicin, and elesclomol, may be considered as potential therapeutic drugs for patients in high-risk groups. Finally, inhibition of AL512306.3 and ZEB1-AS1 significantly suppressed the cell proliferation in colon cancer cells. These results provide novel insights into the pathogenesis of colon cancer and offer promising biomarkers with the potential to guide research on carcinogenesis and cancer treatment.
Indexed as
Identifiers
36504883PMC9729908W4311281451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.